A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis

NCT01945086 ↗

Phase 2 Completed 79 enrolled Janssen Pharmaceutical K.K.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety and effectiveness of 2 doses of ustekinumab compared with placebo (inactive medication) in adult Japanese participants with severe atopic dermatitis.

Timeline

Start: 2013-09
Primary completion: 2014-12
Completion: 2014-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ustekinumab	Monoclonal antibody	45 mg	Subcutaneous
Subject	Ustekinumab	Monoclonal antibody	90 mg	Subcutaneous

A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis

Summary

Timeline

Drugs

Indications